Celldex Therapeutics, Inc.
Income Statement
| Line Item | FY2009 |
|---|---|
| Revenue | $15.2M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $26.2M |
| SG&A Expense | $17.1M |
| Operating Income | $-36.9M |
| Operating Margin | -242.8% |
| Interest Expense | $452.0K |
| Pretax Income | $-37.1M |
| Income Tax Expense | $-529.0K |
| Net Income | $-36.5M |
| Net Margin | -240.6% |
| EPS (Basic) | $0.00 |
| EPS (Diluted) | $0.00 |
| Shares Outstanding (Basic) | 40.95B |
| Shares Outstanding (Diluted) | 40.95B |
| Dividends Per Share | — |